The role of NK cells in the conventional therapy of lung cancer is only partially known; in addition, the possible modifications of NK cell activities and homeostasis upon administration of therapies currently used for lung cancers, ranging from conventional chemotherapy to anti-PD1 blocking mAbs, have been thus far scarcely investigated. This evidence concerns the gene PDCD1 and lung carcinoma.